Goldman Sachs has initiated coverage of Vera Therapeutics (VERA) with a buy rating, citing its drug candidate atacicept and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback